$6.21
-0.17(-2.66%)
Mkt Cap $24M
$1.08
$6.38
52-Week Range
At a Glance
AI-generatedClinical-stage biotech Cyclerion deepened operating losses to -$5.0M amid revenue growth to $2.1M from licensing, while net losses narrowed to -$3.5M and cash burn improved, though management flags cash insufficiency through mid-2026 necessitating new capital.
Revenue breakdown: License Agreement (67.5%), Purchase Agreement (19.6%), Option Agreement (12.9%).
8-K
Cyclerion Therapeutics announced a merger with Korsana Biosciences where Korsana stockholders will own ~98.5% of the combined company, supported by $380M PIPE financing, with closing expected Q3 2026 pending approvals.$24M
Market Cap
$3M
Revenue
-$3M
Net Income
Employees1
Fundamentals
How The Business Makes Money
Revenue by Segment
License Agreement67.5%($3M)
Purchase Agreement19.6%($800.0K)
Option Agreement12.9%($524.0K)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001755237
ISINUS23255M2044
CUSIP23255M105
Phone857 327 8778
Address245 First Street, Cambridge, MA, 02142, US
SEC EDGAR